MariMed reports record FY2024 revenue $158M; Q4 margins compress, adjusted EBITDA up in Q4

MARIMED INC.

Q4 2024 revenue $39.0M (vs $38.9M); full-year revenue $158.0M (+6.3% YoY).
GAAP gross margin fell to 33% in Q4 from 45% YoY; full-year margin 40% vs 44%.
Full-year GAAP net loss improved to $12.1M from $16.0M; adjusted EBITDA $19.6M vs $24.7M.
Wholesale revenue up 29% annually; Betty's Eddies top-selling edible in MA and MD.
CEO cites 10 revenue-generating assets added over past two years for 2025 growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.